The mechanism of cilostazole alleviating intestinal mucosal barrier dysfunction in type 2 diabetic mice
- VernacularTitle:西洛他唑改善2型糖尿病小鼠肠黏膜屏障损伤的机制
- Author:
Pingyi SONG
1
;
Shiqiu JIANG
1
;
Juan HU
1
;
Jialu TAN
1
;
Lan YANG
1
;
Qiang WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: cilostazol; platelet; CD40/CD40L; type 2 diabetes; intestinal barrier
- From: Journal of Xi'an Jiaotong University(Medical Sciences) 2023;44(3):403-408
- CountryChina
- Language:Chinese
- Abstract: 【Objective】 To explore the effect of cilostazol on intestinal barrier function in type 2 diabetes (T2DM). 【Methods】 The GSE142153 dataset was downloaded from GEO database to analyze gene changes in diabetic patients. Eight-week-old male db/db mice and control m/m mice were randomly divided into m/m+cmc, m/m+cilo, db/db+cmc, and db/db+cilo groups. Mice in different groups were given cilostazol and corresponding solvents for 4 weeks. We detected the levels of serum sCD40L and the expression of CD40 in intestinal tissue, and evaluated the mice’s intestinal barrier function by examining intestinal permeability, water content, bacterial number, and tight junction protein expression in different groups. 【Results】 Differential expressed genes were enriched in platelet activation and endothelial barrier function pathways in diabetic patients. Compared with those in the control group, the levels of serum sCD40L in db/db diabetic mice elevated significantly, and the CD40 expression, permeability, water content and bacterial number in intestinal tissue increased obviously, while the expression of tight junction protein decreased. Cilostazol treatment in diabetic mice decreased the levels of serum sCD40L and CD40, and alleviated significantly the intestinal barrier dysfunction. 【Conclusion】 Cilostazol attenuated the damage of intestinal barrier function in T2DM, and its protective effect may be related to the inhibition of platelet activation in diabetic mice.
